Pirfenidone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pirfenidone: From Idiopathic Pulmonary Fibrosis to Extracutaneous Mastocytoma
One-Sentence Summary
Pirfenidone is an antifibrotic agent whose established use is idiopathic pulmonary fibrosis (IPF), acting via inhibition of TGF-β1 signaling and reduction of fibroblast proliferation/collagen synthesis. The TxGNN model predicts it may be effective for Extracutaneous Mastocytoma, but currently 0 clinical trials and 0 publications support this specific direction — this is a model prediction only, with a mechanistically weak rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Idiopathic Pulmonary Fibrosis (IPF) — inferred from mechanistic notes in the evidence pack; no formal indication text is available because the drug carries no active authorization in this jurisdiction |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| EU Market Status | ✗ Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed structured mechanism-of-action (MOA) data is not currently available for this drug in the record (flagged as a High-severity data gap). Based on information embedded in the evidence pack’s rationale notes, Pirfenidone is known to inhibit TGF-β1 signaling and downstream non-SMAD pathways, thereby reducing fibroblast proliferation, myofibroblast activity, and collagen deposition — the pharmacological basis for its established use in idiopathic pulmonary fibrosis.
Extracutaneous mastocytoma, however, is a mast cell proliferative disorder typically driven by KIT mutations (e.g., KIT D816V), not by fibrotic tissue remodeling. There is no established biological pathway connecting TGF-β1/collagen-synthesis inhibition to mast cell proliferation control. The evidence pack itself flags this as a weak mechanistic link.
Consequently, the very high TxGNN score (99.71%) for this pairing is not corroborated by any clinical trial, real-world evidence, or preclinical literature. This pattern — a high similarity/embedding score with no biological or empirical backing — is consistent with a knowledge-graph artifact (e.g., surface-level lexical/semantic proximity) rather than a genuine repurposing signal, and should be treated with caution.
Note on other candidates in this evidence pack: Among the 10 diseases predicted for Pirfenidone, rank #9 (“fibroblastic neoplasm,” score 99.23%) is supported by L3 evidence — including a pilot clinical study in FAP-associated desmoid tumors and multiple in-vitro studies in Dupuytren’s disease fibroblasts — but also carries a safety signal (two case reports of malignant fibroblastic tumor emergence/aggravation during Pirfenidone use). This candidate has materially stronger evidence than the top-ranked prediction discussed above and may warrant separate evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
This drug currently has no active marketing authorization on record in this jurisdiction (market status: Not marketed / Not marketed; total authorizations: 0). No license table can be produced from the evidence pack.
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug-interaction data are marked as data gaps in this evidence pack — notably, TFDA/regulatory label warnings and contraindications are flagged as a Blocking severity gap, meaning safety evaluation cannot proceed until this is resolved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Extracutaneous Mastocytoma) has a high TxGNN score but zero supporting clinical trials, zero literature, and a mechanistically implausible link (antifibrotic TGF-β1 inhibition vs. KIT-driven mast cell proliferation). This is evidence level L5 — model prediction only — and does not meet the bar to advance past initial screening.
To proceed, the following is needed:
- Resolve the Blocking data gap: obtain formal regulatory label warnings/contraindications (source: national regulatory agency label PDF) before any safety-stage (S1) evaluation of Pirfenidone can begin, regardless of indication.
- Obtain structured MOA data from DrugBank (High-severity gap) to properly assess mechanistic plausibility across all 10 predicted indications.
- If pursuing repurposing, prioritize re-evaluation of the fibroblastic neoplasm (Dupuytren’s disease / desmoid tumor) candidate instead, given its stronger L3 evidence base — while also investigating the reported malignant-transformation safety signal before advancing it.
- No further action recommended on the extracutaneous mastocytoma pairing absent new preclinical or clinical data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.